The Vanguard Group 13D and 13G filings for Sarepta Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:13 pm Purchase | 2023-12-29 | 13G | Sarepta Therapeutics, Inc. SRPT | The Vanguard Group | 8,816,124 9.420% | 782,860 (+9.75%) | Filing |
| 2023-02-09 11:32 am Sale | 2022-12-30 | 13G | Sarepta Therapeutics, Inc. SRPT | The Vanguard Group | 8,033,264 9.150% | -277,844 (-3.34%) | Filing |
| 2022-02-10 08:37 am Purchase | 2021-12-31 | 13G | Sarepta Therapeutics, Inc. SRPT | The Vanguard Group | 8,311,108 9.540% | 1,093,849 (+15.16%) | Filing |
| 2021-02-10 11:52 am Purchase | 2020-12-31 | 13G | Sarepta Therapeutics, Inc. SRPT | The Vanguard Group | 7,217,259 9.150% | 832,471 (+13.04%) | Filing |